Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 5Recruiting 3Terminated 2Completed 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 206Prostatic Neoplasms 158Lung Neoplasms 93Stomach Neoplasms 69Neoplasms 69Head and Neck Neoplasms 60Squamous Cell Carcinoma of Head and Neck 56Neoplasm Metastasis 50Esophageal Neoplasms 49Ovarian Neoplasms 39Pancreatic Neoplasms 26Sarcoma 23Carcinoma, Ovarian Epithelial 20Urinary Bladder Neoplasms 19Unspecified Adult Solid Tumor, Protocol Specific 19Breast Neoplasms, Male 17Adenocarcinoma Of Esophagus 17Parkinson Disease 4, Autosomal Dominant Lewy Body 16Esophageal Squamous Cell Carcinoma 16Adenocarcinoma of Lung 16Fallopian Tube Neoplasms 14Carcinoma, Squamous Cell 14Adenocarcinoma 12Melanoma 11Inflammatory Breast Neoplasms 11Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Salivary Gland Neoplasms 8Endometrial Neoplasms 8

Interventions

Trastuzumab 4pyrotinib 2pertuzumab 2Docetaxel 2tucatinib 1trastuzumab deruxtecan 1atezolizumab 1Hospital Information Systems 1Electronic Health Records 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × HER2-positive Breast Cancer × Docetaxel × Clear all
NCT03588091 2025-08-22

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
355 enrolled
Breast

HER2-positive Breast Cancer

NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Cinnagen

Phase 3 Completed
214 enrolled 16 charts
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡